ライフサイエンスコーパス: transbronchial biopsy

1 stable or improving in the weeks leading to transbronchial biopsy.

2 lop once disease recurrence had been seen on transbronchial biopsy.

3 s found to correlate with acute rejection by transbronchial biopsy.

4 treatable infection was diagnosed only with transbronchial biopsy.

5 esence or absence of acute lung rejection on transbronchial biopsy.

6 dpoint was the incidence of ACR on follow-up transbronchial biopsy.

7 red with spirometry and routine surveillance transbronchial biopsies.

8 oscopy with bronchoalveolar lavage (BAL) and transbronchial biopsies.

9 by HRCT, whereas 35.2% had abnormalities on transbronchial biopsies.

10 Ab was determined at the same frequency with transbronchial biopsies.

11 of humoral immunity is a frequent finding on transbronchial biopsies.

12 d on airway brushes outperformed those using transbronchial biopsies.

13 evaluation and fiberoptic bronchoscopy with transbronchial biopsies and bronchoalveolar lavage exclu

14 c diagnoses were made with 29 (34.9%) of the transbronchial biopsies, and patient management was chan

15 aluated by clinical history and examination, transbronchial biopsy, and high-resolution lung computed

16 Transbronchial biopsies are insufficiently sensitive to

17 CCSP-positive cells were assessed in transbronchial biopsies at 1 and 3 months.

18 Airway inflammation in transbronchial biopsies (B score) correlated with NT in

19 Seventy-seven patients had transbronchial biopsies demonstrating BALT.

20 We evaluated complications associated with transbronchial biopsy, diagnostic yield of the procedure

21 Applying this approach to all 896 transbronchial biopsies distinguished 3 groups: no rejec

22 levels from 184 participants at the time of transbronchial biopsies during their first-year post-tra

23 She was a former smoker with a prior transbronchial biopsy for a pulmonary nodule that was ne

24 ly because of the risks and insensitivity of transbronchial biopsy for detecting ACR.

25 Transbronchial biopsies from 29 bronchoscopic procedures

26 Bronchoalveolar lavage (BAL) and transbronchial biopsies from 351 human immunodeficiency

27 Transbronchial biopsies from all lung transplant recipie

28 Longitudinal analysis of transbronchial biopsies from human lung transplant recip

29 rway gene expression changes not apparent in transbronchial biopsies in this cohort.

30 way endobronchial and distal alveolar tissue transbronchial biopsy in a random order at 4:00 P.M. and

31 way endobronchial and distal alveolar tissue transbronchial biopsy in a random order at 4:00 P.M. and

32 tologic associations with BALT identified on transbronchial biopsy in human lung allograft recipients

33 CCSP+ve cells in transbronchial biopsies increased at 3 months only in LT

34 Transbronchial biopsy is performed, and pathology yields

35 the possibility that the presence of BALT on transbronchial biopsy may be part of the evolution of im

36 Transbronchial biopsies (n=104) from 29 human lung trans

37 Transbronchial biopsies of patients receiving single lun

38 ance and 146 patients who underwent ENB with transbronchial biopsy of a lung lesion between 2013 and

39 bronchoscopist improved the success rate of transbronchial biopsy of subcarinal and aortopulmonary l

40 In August X year, we performed a transbronchial biopsy of the right upper lung.

41 obtained by clinically indicated surgical or transbronchial biopsy or cryobiopsy for pathology.

42 Retrospective chart review of all transbronchial biopsies performed within the first 2 yea

43 esently, histologic examination of tissue by transbronchial biopsy remains as the definitive diagnost

44 Transbronchial biopsy revealed adiaspores of the fungus

45 Procuring a good quality transbronchial-biopsy sample is essential for diagnosing

46 se samples (from 25 patients), corresponding transbronchial biopsy samples were available for CMV imm

47 Insufficient transbronchial-biopsy samples are graded "AX." We hypoth

48 ular antigen-staining and rare bacilli while transbronchial biopsies showed granular antigen-staining

49 Pathologic correlation between the transbronchial biopsy specimens and lung tissue obtained

50 sults were obtained in the endobronchial and transbronchial biopsy specimens, which consistently show

51 ults were compared with lavage and endo- and transbronchial biopsy studies in normal controls and pat

52 This retrospective study comprised all transbronchial biopsies (TBB) obtained during the first

53 Histology of transbronchial biopsies (TBB) yields little insight, and

54 onventional methods [BAL microbiological and transbronchial biopsy (TBB) analyses].

55 ografts using endobronchial biopsy (EBB) and transbronchial biopsy (TBB) from 22 lung transplant pati

56 infiltration in alveolar tissue samples from transbronchial biopsies (TBBs).

57 study of consecutive patients who underwent transbronchial biopsy (TBBx) for evaluation of periphera

58 Descriptions of eosinophils in transbronchial biopsy (TBBx) pathology reports after lun

59 apeutic aspiration of airway secretions, and transbronchial biopsy to diagnose parenchymal lung disor

60 Transbronchial biopsy to sample lymph nodes and tumors t

61 For messenger RNA in transbronchial biopsies, trends (p > 0.05 and <or= 0.10)

62 d for a similar molecular ABMR-like state in transbronchial biopsies using gene expression microarray

63 A expression from small airway brushings and transbronchial biopsies, using RNAseq and digital RNA co

64 Transbronchial biopsy was performed in 36 patients, of w

65 Transbronchial biopsies were also obtained when possible

66 Endobronchial and transbronchial biopsies were performed in selected patie

67 All transbronchial biopsies were regraded 0 to 4 for acute p